AVXL - Anavex Life Sciences Corp

AVXL - Anavex Life Sciences Corp

https://www.anavex.com

Strong Sell Momentum: Bearish

Recent News

Powered by Alpha Vantage

Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows - Anavex Life Sciences ( NASDAQ:AVXL )

Benzinga • 3 weeks, 5 days ago • score: 0.14

Pre-treatment with blarcamesine prevented memory impairment in Alzheimer's mouse model. SIGMAR1 activation linked to reduced oxidative stress and restored cellular balance. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. Anavex Life Sciences Corp.

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 - Anavex Life Sciences ( NASDAQ:AVXL )

Benzinga • 1 month, 1 week ago • score: 0.05

NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

GlobeNewswire • 1 month, 1 week ago • score: 0.04

Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET ...

Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences ( AVXL ) is a Great Choice

Zacks Commentary • 2 months ago • score: 0.43

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Anavex Life Sciences Corp. The company is headquartered in New York, New York.

52W High

$14.44

52W Low

$4.93

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.83

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

3.97

EV/EBITDA (<8 favorable)

-5.54

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

8.88

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

3.31%

Institutions (25–75% balanced)

38.38%

Shares Outstanding

85,894,000

Float

83,048,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.57

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.44%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.2960

Previous

-0.3033

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025